Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024 4:01 PM EDT- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies
- Alpines lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 -
- Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway -
- Alpines protein engineering and immunotherapy expertise augments Vertexs toolbox and capabilities -
- Vertex to host investor call today, April 10, at 4:30 pm ET -
BOSTON &... More
